You will be randomly assigned to receive either Golcadomide in combination with Rituximab (Golca + R) or an Investigator’s Choice treatment for your relapsed/refractory follicular lymphoma (a type of blood cancer that affects the lymphatic system and has returned or not responded to previous treatment).

If assigned to the Golcadomide plus Rituximab group: You will take Golcadomide orally in capsule form, and receive Rituximab, which is given through an intravenous (IV) infusion (directly into your vein).

If assigned to the Investigator’s Choice group: You may receive one of several standard treatments which could include combinations of medications such as bendamustine hydrochloride, cyclophosphamide, lenalidomide, rituximab, betamethasone sodium phosphate, prednisone, doxorubicin hydrochloride, vincristine sulfate, or pegfilgrastim. The specific regimen will be determined by your doctor.

Throughout the study, you will have regular visits to evaluate how your cancer is responding to treatment. These assessments will follow the Lugano 2014 classification guidelines, which are standard criteria for evaluating lymphoma response.

Assessments will include blood tests, imaging studies, and physical examinations to monitor your cancer and any side effects from treatment.

You will complete questionnaires about how you feel and how the treatment is affecting your daily life. These help researchers understand the impact of treatment beyond just the medical effects.

Your cancer will be regularly monitored to check if it is responding to treatment, staying stable, or progressing (getting worse).

If your disease progresses, this will be documented as part of the study’s primary measurement (progression-free survival).

After completing treatment, you will enter a follow-up period where your health will continue to be monitored.

The study will track how long you live overall, whether you need to start new treatments, and the long-term outcomes of your cancer response.

The study is expected to run until July 14, 2025, with final data collection for the primary outcome measure.

The entire study, including long-term follow-up, is anticipated to continue until November 6, 2027.